daunorubicin has been researched along with bortezomib in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Bousquet-Dubouch, MP; Burlet-Schiltz, O; Gallay, N; Manenti, S; Matondo, M; Monsarrat, B; Payrastre, B; Recher, C; Uttenweiler-Joseph, S | 1 |
| Lin, MF; Ouyang, GF | 1 |
| Gong, YP; Yang, X; Zheng, BH; Zhou, RQ | 1 |
| Chang, H; Gong, YP; Xing, HY; Yang, L; Yang, X; Zheng, BH; Zhou, RQ | 1 |
| Gong, Y; Shan, Q; Yang, X; Zheng, B; Zhou, R | 1 |
| Amrein, PC; Attar, EC; Bloomfield, CD; Blum, W; DeAngelo, DJ; Johnson, JL; Kolitz, JE; Larson, RA; Lozanski, G; Marcucci, G; Moser, B; Powell, BL; Stone, RM; Voorhees, P; Wadleigh, M; Wang, ES | 1 |
| Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z | 1 |
| Fu, BB; Li, J; Li, YC; Liao, AJ; Liu, ZG; Wang, HH; Yang, W; Yang, Y; Zhang, R | 1 |
| Du, S; Du, X; He, C; Jia, P; Li, J; Lu, H; Shen, Z; Tong, J; Wu, Y; Xu, H; Zhao, W; Zhou, L | 1 |
| Adamcova, M; Brazdova, P; Hlavackova, M; Holzerova, K; Jansova, H; Jirkovska, A; Jirkovsky, E; Kolar, F; Kubes, J; Lencova-Popelova, O; Mazurova, Y; Pokorna, Z; Simunek, T; Sotakova-Kasparova, D; Sterba, M; Vostatkova, L | 1 |
| Bhatia, S; Borkhardt, A; Christianson, DW; Hansen, FK; Hauer, J; Kassack, MU; Osko, JD; Reßing, N; Schliehe-Diecks, J; Schöler, A; Skerhut, A; Sönnichsen, M | 1 |
1 review(s) available for daunorubicin and bortezomib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for daunorubicin and bortezomib
| Article | Year |
|---|---|
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Topics: Aged; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Drug Synergism; Female; Follow-Up Studies; Histocompatibility Antigens Class II; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Nervous System; Pyrazines; Remission Induction; Survival Analysis; Treatment Outcome | 2013 |
12 other study(ies) available for daunorubicin and bortezomib
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Daunorubicin; Drug Resistance, Neoplasm; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Leupeptins; Male; Middle Aged; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured; U937 Cells | 2010 |
Combined effects of bortezomib and daunorubicin on multiple myeloma cell KM3 in vitro.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Drug Synergism; Humans; Inhibitory Concentration 50; Multiple Myeloma; Pyrazines | 2009 |
[Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Daunorubicin; Drug Synergism; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Tumor Cells, Cultured; Young Adult | 2010 |
[The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Daunorubicin; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Pyrimidines | 2010 |
Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; Humans; K562 Cells; Leukemia; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2012 |
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Molecular mechanisms of converting K562/DNR cellular drug-resistance by bortezomib.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Daunorubicin; Drug Resistance, Neoplasm; Humans; I-kappa B Proteins; K562 Cells; NF-kappa B; Pyrazines | 2014 |
Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Bcl-2-Like Protein 11; Bortezomib; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Daunorubicin; Drug Synergism; Gene Expression; Humans; Jurkat Cells; Membrane Potential, Mitochondrial; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2017 |
Topics: Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiotoxicity; Daunorubicin; Dose-Response Relationship, Drug; Male; Myocytes, Cardiac; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Rabbits; Rats; Rats, Wistar | 2019 |
Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
Topics: Animals; Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Daunorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Epirubicin; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Microsomes, Liver; Molecular Structure; Protein Binding; Structure-Activity Relationship; Tetrazoles | 2020 |